Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
Justin StebbingYauheni BaranauValery BaryashVladimir MoiseyenkoDmytro BoliukhNicoleta AntoneAlexey ManikhasAnatolii ChornobaiTae Hong ParkEric Hyungseok BaekJaeyong LeeJiin ChoiNahyun KimKeum Young AhnSang Joon LeeSunghyun KimPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
2019-003518-15 (retrospectively registered 10 March 2020).
Keyphrases